Hospital Stocks In Focus: Analysts See Limited Earnings Hit From 30% Cancer Drug Margin Cap ↗
Goldman Sachs' discussions with hospitals and industry participants suggest that the impact of the new price controls is likely to be minimal across most multi-specialty hospital chains.
Open on desktop to take part.
0 comments
Comments are posted by users and are not reviewed by Bazaar Updates.
Open on desktop to take part.
Sign in to comment.
No comments yet.